RP

Rivus Pharmaceuticals at ObesityWeek 2026

Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website

Rivus Pharmaceuticals brings 3 presentations to ObesityWeek 2026 in National Harbor. Its program centres on RV-8451, a preclinical GLP-1 receptor compound aimed at fat-specific weight loss that spares muscle. It covers mouse studies in which RV-8451 outperforms orforglipron and reverses the muscle loss that orforglipron causes.

OrganizationObesityWeek 2026 Attendance
RP
Rivus Pharmaceuticals
Charlottesville, VA
Biotech
Develops obesity and metabolic drugs aimed at fat loss while preserving muscle, including a preclinical GLP-1 receptor agonist.
Poster
Sat Nov 14
7:30pm–8:30pm

Explore the full ObesityWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in National Harbor. Leave your work email and we’ll be in touch.

Privacy

Download the full ObesityWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Rivus Pharmaceuticals

Tell us what you sell and we’ll find the people at Rivus Pharmaceuticals most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction